Prognostic Nutritional Index Predicts Efficacy and Immune-Related Adverse Events of First-Line Chemoimmunotherapy in Patients with Extensive-Stage Small-Cell Lung Cancer

References

• Wang Q, Gümüş ZH, Colarossi C, et al. SCLC: epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J Thoracic Oncol. 2023;18(1):31–46. doi:10.1016/j.jtho.2022.10.002
   PubMed Web of Science ®Google Scholar
• Megyesfalvi Z, Gay CM, Popper H, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. Ca a Cancer J Clinicians. 2023;73(6):620–652. doi:10.3322/caac.21785
   PubMed Web of Science ®Google Scholar
• Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. New Engl J Med. 2002;346(2):85–91. doi:10.1056/NEJMoa003034
   PubMed Web of Science ®Google Scholar
• Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999;17(11):3540–3545. doi:10.1200/JCO.1999.17.11.3540
   PubMed Web of Science ®Google Scholar
• Pelayo Alvarez M, Gallego Rubio O, Bonfill Cosp X, Agra Varela Y. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev. 2009;1(4):Cd001990.
   Google Scholar
• Wolf M, Tebbe S, Fink T. First-line chemotherapy in metastatic small-cell lung cancer (SCLC). Lung Cancer. 2004;45 Suppl 2:S223–234.
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhang Z, Luo F, et al. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: a Systematic Review and Network Meta-analysis. JAMA network open. 2020;3(10):e2015748. doi:10.1001/jamanetworkopen.2020.15748
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, Phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Mathieu L, Shah S, Pai-Scherf L, et al. FDA Approval Summary: atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. oncologist. 2021;26(5):433–438. doi:10.1002/onco.13752
   PubMed Web of Science ®Google Scholar
• Barrows ED, Blackburn MJ, Liu SV. Evolving role of immunotherapy in small cell lung cancer. Semi Cancer Biol. 2022;86(Pt 3):868–874. doi:10.1016/j.semcancer.2022.02.021
   PubMedGoogle Scholar
• Zhang C, Wang H. Accurate treatment of small cell lung cancer: current progress, new challenges and expectations. Biochim. Biophys. Acta, Rev. Cancer. 2022;1877(5):188798. doi:10.1016/j.bbcan.2022.188798
   PubMed Web of Science ®Google Scholar
• Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. J Thoracic Oncol. 2021;16(7):1086–1098. doi:10.1016/j.jtho.2021.03.017
   PubMed Web of Science ®Google Scholar
• Longo V, Catino A, Montrone M, et al. What Are the Biomarkers for Immunotherapy in SCLC? Int J Mol Sci. 2021;22(20):11123. doi:10.3390/ijms222011123
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Lamberti G, Parisi C, et al. The evolving landscape of immunotherapy in small-cell lung cancer: a focus on predictive biomarkers. Cancer Treat Rev. 2019;79:101887. doi:10.1016/j.ctrv.2019.08.003
   PubMed Web of Science ®Google Scholar
• Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol. 2021;18(5):261–279. doi:10.1038/s41571-020-00459-9
   PubMed Web of Science ®Google Scholar
• Ritter B, Greten FR. Modulating inflammation for cancer therapy. J Exp Med. 2019;216(6):1234–1243. doi:10.1084/jem.20181739
   PubMed Web of Science ®Google Scholar
• Guo Y, Xiang D, Wan J, Yang L, Zheng C. Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: a Meta-Analysis and Systematic Review. Cancers. 2022;14(21):5297. doi:10.3390/cancers14215297
   PubMed Web of Science ®Google Scholar
• Xu H, He A, Liu A, Tong W, Cao D. Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Int Immunopharmacol. 2019;77:105957. doi:10.1016/j.intimp.2019.105957
   PubMed Web of Science ®Google Scholar
• Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13(1):158. doi:10.1186/1471-2407-13-158
   PubMedGoogle Scholar
• Wang Z, Wang Y, Zhang X, Zhang T. Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: review and meta-analysis. Int j Clin Chem. 2018;486:303–310. doi:10.1016/j.cca.2018.08.030
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74. doi:10.1186/s40425-018-0383-1
   PubMed Web of Science ®Google Scholar
• Gu XB, Tian T, Tian XJ, Zhang XJ. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015;5(1):12493. doi:10.1038/srep12493
   PubMed Web of Science ®Google Scholar
• Gu X, Sun S, Gao XS, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3430 patients. Sci Rep. 2016;6(1):23893. doi:10.1038/srep23893
   PubMedGoogle Scholar
• Johannet P, Sawyers A, Qian Y, et al. Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J Immunother Cancer. 2020;8(2):e001674. doi:10.1136/jitc-2020-001674
   PubMed Web of Science ®Google Scholar
• Watanabe I, Kanauchi N, Watanabe H. Preoperative prognostic nutritional index as a predictor of outcomes in elderly patients after surgery for lung cancer. Jpn J Clin Oncol. 2018;48(4):382–387. doi:10.1093/jjco/hyy014
   PubMed Web of Science ®Google Scholar
• National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03; 2009. Available at https://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf. Accessed March 13, 2024.
   Google Scholar
• Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). Cancer. 2020;126(2):260–270. doi:10.1002/cncr.32468
   PubMed Web of Science ®Google Scholar
• Liu SV, Reck M, Mansfield AS, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39(6):619–630. doi:10.1200/JCO.20.01055
   PubMed Web of Science ®Google Scholar
• Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;38(21):2369–2379. doi:10.1200/JCO.20.00793
   PubMed Web of Science ®Google Scholar
• Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nature Reviews Disease Primers. 2021;7(1):3. doi:10.1038/s41572-020-00235-0
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Callahan MK, Awad MM, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018;33(5):853–861.e854. doi:10.1016/j.ccell.2018.04.001
   PubMed Web of Science ®Google Scholar
• Li Q, Ma F, Wang JF. Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy. Front Oncol. 2023;13:997314. doi:10.3389/fonc.2023.997314
   PubMed Web of Science ®Google Scholar
• Mountzios G, Samantas E, Senghas K, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open. 2021;6(5):100254. doi:10.1016/j.esmoop.2021.100254
   PubMed Web of Science ®Google Scholar
• Hou W, Zhou X, Yi C, Zhu H. Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer. Front Oncol. 2021;11:604227. doi:10.3389/fonc.2021.604227
   PubMed Web of Science ®Google Scholar
• Fu Y, Zheng Y, Wang PP, Ding ZY. Toxicities of Immunotherapy for Small Cell Lung Cancer. Front Oncol. 2021;11:603658. doi:10.3389/fonc.2021.603658
   PubMedGoogle Scholar
• Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother. 2020;69(9):1813–1822. doi:10.1007/s00262-020-02585-w
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306. doi:10.1186/s40425-019-0805-8
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.016
   PubMed Web of Science ®Google Scholar